Matt Lorenzi,

Vice President, Oncology Ventures and External Innovation

Matt Lorenzi, Ph.D. is Vice President, Oncology Ventures & Scientific Innovation, Oncology Therapeutic Area, Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. In this role, Matt is responsible for the direction and execution external innovation strategies for the oncology therapeutic area for Western North America. In addition, Matt is leading the creation of new asset and platform oncology companies for externalization. Prior to his current role, Matt led the Solid Tumor Targeted Therapy Disease Area in Janssen Oncology focused on therapeutically targeting the key genetic defects and resistance mechanisms underlying solid tumor pathobiology. During his tenure at Janssen, Matt advanced strong discovery and translational research to collaboratively deliver a robust preclinical and clinical pipeline of novel immunotherapy and targeted agents leading to the approval of BALVERSA (erdafitinib) and RYBREVANT (amivantamab) targeting the oncogenic drivers FGFR and EGFR, respectively. In addition, Matt advanced important external innovation opportunities including the acquisitions of Taris and Benevir as well as the in-licensing of lazertinib from Yuhan Pharmaceuticals.

Prior to joining Janssen, Matt was a senior oncology leader at Bristol-Myers Squibb where he directed teams focused on small molecule and biologics-based drug discovery and development. Within these roles, he brought strong scientific and strategic leadership to successfully deliver multiple agents into and through clinical development.

Matt received his Ph.D. from the University of Miami in Molecular Pharmacology where he was a PhRMA Foundation Pre-Doctoral Fellow. He conducted his post-doctoral fellowship at the National Cancer Institute in Bethesda, MD where he continued as a tenure-track Senior Staff Fellow. His research on the molecular events underlying cancer development have led to the identification of new cancer driver pathways and novel therapeutics for cancer patients.

Matt Lorenzi
Matt Lorenzi